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Abstract Our aim was to study the association between
country of birth and incidence of gout in different immigrant
groups in Sweden. The study population included the whole
population of Sweden. Gout was defined as having at least
one registered diagnosis in the National Patient Register. The
association between incidence of gout and country of birth
was assessed by Cox regression, with hazard ratios (HRs) and
95% confidence intervals (95% CI), using Swedish-born in-
dividuals as referents. All models were conducted in both
men and women, and the full model was adjusted for age,
place of residence in Sweden, educational level, marital sta-
tus, neighbourhood socio-economic status and co-morbid-
ities. The risk of gout varied by country of origin, with
highest estimates, compared to Swedish born, in fully
adjusted models among men from Iraq (HR 1.82, 95% CI
1.54–2.16), and Russia (HR 1.69, 95% CI 1.26–2.27), and
also high among men from Austria, Poland, Africa and Asian
countries outside the Middle East; and among women from
Africa (HR 2.23, 95% CI 1.50–3.31), Hungary (HR 1.98,
95% CI 1.45–2.71), Iraq (HR 1.76, 95% CI 1.13–2.74) and
Austria (HR 1.70, 95% CI 1.07–2.70), and also high among
women from Poland. The risk of gout was lower among men
from Greece, Spain, Nordic countries (except Finland) and
Latin America and among women from Southern Europe,
compared to their Swedish counterparts. The increased risk
of gout among several immigrant groups is likely explained
by a high cardio-metabolic risk factor pattern needing
attention.
Key messages 1. We found both increased and decreased risk of gout in
different immigrant groups compared to Swedish-born individuals.
2. Our findings with lower gout risk among immigrants from Southern
Europe and Latin America suggest a possible preventive effect on gout by
Mediterranean diet.
3. The increased risk of gout among several immigrant groups is likely
explained by a high cardio-metabolic risk factor pattern needing attention.
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Introduction
Gout is the most common inflammatory arthritis where
monosodium urate crystals are deposited in joints and soft
tissues. Individuals with gout experience acute attacks of ex-
cruciating pain; and, if left untreated, gout may lead to debil-
itating complications such as chronic joint damage and renal
insufficiency [1]. All these contribute to the poor patient’s
health-related quality of life [2].
In addition, gout is also associated with different metabolic
conditions, such as insulin resistance [3], the metabolic syn-
drome and diabetes mellitus [4]. Besides, there is also a strong
relationship between gout and hypertension and with antihy-
pertensive diuretic treatment [5, 6], especially with thiazide
diuretics [7, 8], and with other cardio-vascular diseases such
as chronic heart failure [5] and chronic kidney disease [9].
Gout is also associated with an increased mortality risk, main-
ly through the increased risk of cardio-vascular diseases, in-
cluding coronary heart disease [10].
As a metabolic disorder, gout is associated with several
established risk factors according to epidemiological studies
[11]: genetic factors, excess alcohol consumption [12] and
with a purine-rich diet, especially with high rate of hypoxan-
thine, i.e. diets with animal meats, fish meats, organs such as
liver and fish milt and yeast [13].
Recent review of epidemiological evidence has indicated
that gout has risen worldwide over the last few decades [1],
tailing the obesity epidemic [11]. Besides, the clinical picture
of gout seems to have become more complex [11]. However,
there is a large variation in the prevalence data of gout.
Evidence from a recent review and meta-regression indicates
that age, sex, continent on which study was performed and the
case definition of gout accounted for the large variation in
gout prevalence across studies [9]. Indeed, ageing is a risk
factor for gout in both sexes; however, gout is more prevalent
in men than in women [14, 15]. Furthermore, there are signif-
icant differences in prevalence of gout across the continents
where the highest prevalencewith estimates of >10% has been
observed in Oceanian countries and a high prevalence of 1–
4% in most countries in North America and Western Europe
[16]. Lower prevalence has been observed in former Soviet
Union regions, Guatemala, Philippines, Malaysia, Iran, rural
Turkey, Saud Arabia and African countries.
In Sweden, almost one fifth of the population is foreign
born, and immigration to Sweden increases with each year
[17]. Describing and better understanding of disparities in
gout among immigrants are of great interest both for the health
care and the society in general for possible preventive actions.
The aim of this study was to explore the risk of being diag-
nosed with gout among first- and second-generation immi-
grants in Sweden.
Methods
Design
The dataset used in this study was retrieved from governmen-
tal national registers such as the Total Population Register
(TPR) and the National Patient Register (NPR) that contain
longitudinal information on the entire population of Sweden
for a period of 40 years. The TPR contains comprehensive
nationwide individual-level data as well as data on
neighbourhood socio-economic status (SES). The Swedish
nationwide population and health care registers have excep-
tionally high completeness and validity [18]. Individuals were
tracked using their personal identification numbers, which are
assigned to each resident of Sweden. These identification
numbers were replaced with serial numbers to provide ano-
nymity. Subjects of 45 years of age and older were included in
the study. The follow-up period ran from January 1, 1998 until
hospitalization/outpatient treatment of gout at death, emigra-
tion or December 31, 2012, whichever came first.
Study population and co-morbidities
This study included the whole Swedish population. Country
of birth was registered, and we included 10 regions (Nordic
countries, Southern Europe, Western Europe, Eastern Europe,
Baltic countries, Central Europe, Africa, North America, Latin
America and Asia) and 27 countries (Supplementary Table 1).
Countries with less than 10 observed cases of gout were not
analysed separately. The second-generation immigrants were
defined according to the Swedish Multi-generation Register,
based on their parental immigrant’s information.
The reference population in the analysis for the second-
generation immigrants was Swedes in at least two generations
that are adults 45 years of age and older born in Sweden and
with both father and mother born in Sweden.
Patients with diagnosed gout were identified by the pres-
ence of the ICD-10 code (tenth version of the WHO’s
International Classification of Diseases) for gout (M10) in
the National Patient Register. Patients with gout diagnosed
before 1998, i.e. during the years 1987–1997 (according to
ICD-9 1987–1996 and ICD-10 1997) were excluded.
We also identified co-morbidities according to ICD-10 for
the following diagnoses: hypertension I10–I19, coronary heart
disease (CHD) I20–I25, heart failure I50, stroke I60–I69, di-
abetes E10–E14, obesity E65–E68, alcoholism and related
disorders F10 and K70 and chronic obstructive pulmonary
disease (COPD) J40–J47.
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Outcome variable
Gout ICD-10 code M10.
Demographic and socio-economic variables
Sex: men and women.
Age was used as a continuous variable in the analysis.
Educational attainment was categorized as ≤9 years (par-
tial or complete compulsory schooling), 10–12 years (partial
or complete secondary schooling) and >12 years (attendance
at college and/or university).
Geographic region of residence was included in order to
adjust for possible regional differences in hospital admissions
and was categorized as (1) large cities, (2) southern Sweden
and (3) northern Sweden. Large cities were defined as munic-
ipalities with a population of >200,000 and comprised the three
largest cities in Sweden: Stockholm, Gothenburg and Malmö.
Neighbourhood socio-economic status
The neighbourhoods were derived from small-area market sta-
tistics (SAMS), which were originally created for commercial
purposes and pertain to small geographic areas with boundaries
defined by homogenous types of buildings. The average pop-
ulation in each SAMS neighbourhood is approximately 2000
people for Stockholm and 1000 people for the rest of Sweden.
A summary index was calculated to characterize
neighbourhood-level deprivation. The neighbourhood index
was based on information about female and male residents
aged 20 to 64 years, because this age group represents those
who are among the most socio-economically active in the pop-
ulation (i.e. a group that has a stronger impact on the socio-
economic structure in the neighbourhood compared to children,
younger women andmen and retirees). The indexwas based on
the following four variables: low educational status (<10 years
of formal education); income from all sources, including inter-
est and dividends, that is <50% of the median individual in-
come; unemployment (excluding full-time students, those com-
pleting military service and early retirees); and receipt of social
welfare. The index was categorized into three groups: more
than one standard deviation (SD) below the mean (high SES
or low deprivation level), more than one SD above the mean
(low SES or high deprivation level) and within one SD of the
mean (middle SES or deprivation level) [19], with
neighbourhood status classified as high, middle or low SES
or on low, middle and high deprivation index [20].
Statistical analysis
Baseline subject characteristics were presented for population
samples when estimating incidence rates of gout among first-
generation immigrants and among second-generation immigrants.
Cox regression was used for estimating the risk for gout in
different immigrant groups compared to Swedish born as ref-
erents. Time was from January 1, 1998, or immigration date
until hospitalization/outpatient treatment of gout at diagnosis,
death, emigration or the end of the study period on December
31, 2012.
All analyses were stratified by sex. Four models were used:
model 1 was adjusted for age and region of residence in
Sweden; model 2 was adjusted for age, region of residence
in Sweden, educational level and marital status; model 3 was
as model 2 with the addition of neighbourhood SES; and
model 4 was as model 3 with the addition of co-morbidities.
As a sensitive analysis, we also analysed hazard ratios (HRs)
for first-generation immigrants with exclusion of immigrants
who moved to Sweden within 5 years of follow-up with full
adjustment according to model 4.
The study was approved by the local ethical vetting board
at the Karolinska Institutet (reference number 12/00 EPN
Huddinge at 6 March 2000, approval of addition at 18
November 2002).
Results
Table 1 presents the characteristics of the included samples for
first- and second-generation immigrants. Among the first-
generation immigrants, 0.5% were diagnosed with gout, i.e.
0.8% among men and 0.3% among women, while among
second-generation immigrants, 0.3% were diagnosed with
gout. In general, the incidence of gout tended to be lower
among both first- and second-generation immigrants than
Swedish born, higher among lower educated and lower
among higher educated, higher among residents in the larger
cities and lower in northern Sweden and higher among indi-
viduals with co-morbidities, especially cardio-vascular co-
morbidities.
Table 2 presents risk of gout in first-generation male immi-
grants compared to their Swedish-born counterparts. After
adjustment for age, region of residence in Sweden, education-
al level, marital status and neighbourhood deprivation (model
3) and compared to Swedish-born men, the risk of gout was
higher among male immigrants with origin from Austria;
Poland; Russia; and African and Asian continents, especially
Iraq. In contrast, compared to Swedish-born men, the risk of
gout was lower in men originating from Denmark; Norway;
Southern Europe, especially Greece and Spain; and Latin
America, especially Chile. After additional adjustment for
co-morbidities (model 4), the estimates were somewhat atten-
uated but mostly with marginal changes.
Table 3 presents risk of gout in first-generation female im-
migrants compared to Swedish-born women. After adjust-
ment for age, region of residence in Sweden, educational lev-
el, marital status and neighbourhood deprivation (model 3),
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Table 1 Population and number
of cases of events (with
percentages) in first generation
and second generation
First generation Second generation
Population Gout events Population Gout events
No. % No. % No. % No. %
Total population 6,449,369 32,956 6,874,682 18,212
Gender
Males 3,051,102 47.3 22,919 69.5 3,508,632 51.0 14,511 79.7
Females 3,398,267 52.7 10,037 30.5 3,366,050 49.0 3701 20.3
Immigrant statusa
Sweden 5,306,288 82.3 28,900 87.7 5,666,670 82.4 16,287 89.4
Other countries 1,143,081 17.7 4056 12.3 1,208,012 17.6 1925 10.6
Birth year
−1909 79,034 1.2 328 1.0
1910–19 349,829 5.4 3615 11.0
1920–29 628,432 9.7 8270 25.1
1930–39 733,408 11.4 7534 22.9 447,284 6.5 4246 23.3
1940–49 1,093,953 17.0 6495 19.7 1,039,756 15.1 6119 33.6
1950–59 1,027,898 15.9 3702 11.2 1,035,473 15.1 3812 20.9
1960–69 1,101,200 17.1 2129 6.5 1,153,201 16.8 2370 13.0
1970– 1,435,615 22.3 883 2.7 3,198,968 46.5 1665 9.1
Educational level
≤9 2,015,602 31.3 15,352 46.6 1,772,765 25.8 5894 32.4
10–12 1,628,711 25.3 8570 26.0 1,476,803 21.5 5791 31.8
>12 2,805,056 43.5 9034 27.4 3,625,114 52.7 6527 35.8
Region of residence
Large cities 2,068,774 32.1 13,444 40.8 2,046,576 29.8 7463 41.0
Southern Sweden 2,696,245 41.8 14,039 42.6 2,653,219 38.6 7619 41.8
Northern Sweden 1,684,350 26.1 5473 16.6 2,174,887 31.6 3130 17.2
Marital status
Married 4,758,618 73.8 23,425 71.1 4,719,785 68.7 10,860 59.6
Unmarried 1,690,751 26.2 9531 28.9 2,154,897 31.3 7352 40.4
Neighbourhood deprivation
Low 891,126 13.8 4420 13.4 939,288 13.7 2668 14.6
Middle 3,043,079 47.2 16,065 48.7 2,977,688 43.3 8644 47.5
High 722,008 11.2 3720 11.3 684,085 10.0 1979 10.9
Unknown 1,793,156 27.8 8751 26.6 2,273,621 33.1 4921 27.0
Hospital diagnosis of COPD
No 6,160,669 95.5 28,777 87.3 6,598,004 96.0 16,394 90.0
Yes 288,700 4.5 4179 12.7 276,678 4.0 1818 10.0
Hospital diagnosis of obesity
No 6,364,017 98.7 31,844 96.6 6,768,237 98.5 17,216 94.5
Yes 85,352 1.3 1112 3.4 106,445 1.5 996 5.5
Hospital diagnosis of CHD
No 5,916,045 91.7 22,145 67.2 6,656,575 96.8 14,577 80.0
Yes 533,324 8.3 10,811 32.8 218,107 3.2 3635 20.0
Hospital diagnosis of diabetes
No 6,099,921 94.6 26,181 79.4 6,656,003 96.8 14,950 82.1
Yes 349,448 5.4 6775 20.6 218,679 3.2 3262 17.9
Hospital diagnosis of alcoholism and related disorders
No 6,313,123 97.9 31,197 94.7 6,689,528 97.3 16,531 90.8
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the risk of gout was higher among immigrant women from
Austria; Romania; Central Europe, especially Poland and
Hungary; Africa and Asia, especially Turkey and Iraq; while
a lower risk of gout was observed for immigrant women with
origin not only from Southern Europe but also from North
America compared to Swedish-born women. Additional ad-
justment for co-morbidities (model 4) attenuated the esti-
mates, and these were no longer significant for women from
Romania and Turkey and were with borderline significance
among Polish women. When performing a sensitive analysis
excluding immigrants who moved to Sweden within 5 years
of follow-up, the estimates were very similar (Supplementary
Tables 2 and 3).
Tables 4 and 5 present the risk of gout in second-generation
male and female immigrants, respectively, compared to their
Swedish-born counterparts. After adjusting for age, region of
residence, educational level, marital status and neighbourhood
SES (model 3), the risk of gout was higher among male im-
migrants with origin from the Nordic countries, especially
Finland, and from Central Europe, especially Poland and in
immigrants from the former Yugoslavia. In contrast, com-
pared to Swedish-born men, the risk of gout was lower in
men originating from Greece. Furthermore, second-
generation immigrant women from the Nordic countries had
lower risk for gout compared to their Swedish-born counter-
parts. With additional adjustment for co-morbidities (model
4), the estimates were somewhat attenuated.
Discussion
We explored the risk of being diagnosed with gout in first- and
second-generation immigrant men and women than their
Swedish-born counterparts, with a total prevalence of 0.5%.
Themost prominent differences in rates of gout were observed
between first-generation immigrants and in Swedish-born
people. Risk of being diagnosed with gout was higher not only
among first-generation immigrants from several European
countries but also among immigrants from Africa and some
Asian countries, while the risk of being diagnosed with gout
was lower among first-generation immigrants in some
Southern European countries and among second-generation
immigrant men from Greece. The differences in gout rates
between the second-generation immigrant men and their
Swedish-born counterparts were less apparent, while almost
no difference was noted among women. The latter, however,
may have been due to a low number of events.
When looking at the risk of gout among immigrants from
European countries and the estimated prevalence in these
countries, some interesting differences could be noted.
Prevalence of gout is reported to be highest in Greece, with
slightly lower figures from the UK, the Netherlands and
Spain, while the lowest prevalence is reported from Portugal
and the Czech Republic, with also low figures from France
and Italy [16]. We found lower estimates for immigrants from
Southern Europe, for men among first-generation immigrants
from Greece and Spain, and among second-generation immi-
grants from Greece, in contrast to the reported prevalence
figures from these countries. Low prevalence of gout in the
world is reported from Asian countries, including the Middle
East, African countries and at least from one country, i.e.
Guatemala, in Latin America [16]. In contrast to these find-
ings, we found higher gout risk among first-generation immi-
grants from Middle East countries and Africa.
We have no certain explanation for the disagreement be-
tween our study and earlier prevalence figures, e.g. the high
Table 1 (continued)
First generation Second generation
Population Gout events Population Gout events
No. % No. % No. % No. %
Yes 136,246 2.1 1759 5.3 185,154 2.7 1681 9.2
Hospital diagnosis of stroke
No 6,077,938 94.2 27,275 82.8 6,741,870 98.1 16,462 90.4
Yes 371,431 5.8 5681 17.2 132,812 1.9 1750 9.6
Hospital diagnosis of hypertension
No 5,689,298 88.2 18,884 57.3 6,422,170 93.4 11,053 60.7
Yes 760,071 11.8 14,072 42.7 452,512 6.6 7159 39.3
Hospital diagnosis of heart failure
No 6,126,173 95.0 22,043 66.9 6,797,635 98.9 15,298 84.0
Yes 323,196 5.0 10,913 33.1 77,047 1.1 2914 16.0
All differences between the population and patients diagnosed with gout were statistically significant (p < 0.001)
a Immigrant status in second generation was based on parental birth country
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gout prevalence in Greece and the low gout risk among Greek
immigrants we found. However, emigrants from a specific
country or region may differ from those staying in their
country of origin, i.e. migrants often tend to be healthier (the
Bhealthy migrant effect^), even if many immigrants retain
many of their dietary habits. The low estimates in some groups
Table 2 The risk of gout in first-
generation male immigrants Country/region of origin Model 1 Model 2 Model 3 Model 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sweden 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Nordic countries 0.93 (0.87–0.99) 0.92 (0.86–0.98) 0.94 (0.88–1.00) 0.87 (0.82–0.93)
Denmark 0.75 (0.64–0.88) 0.74 (0.64–0.87) 0.75 (0.64–0.88) 0.76 (0.65–0.89)
Finland 1.05 (0.90–1.13) 1.03 (0.95–1.10) 1.06 (0.98–1.14) 0.94 (0.87–1.01)
Norway 0.70 (0.58–0.85) 0.71 (0.59–0.85) 0.72 (0.60–0.87) 0.74 (0.62–0.90)
Southern Europe 0.65 (0.55–0.78) 0.65 (0.54–0.77) 0.67 (0.56–0.80) 0.74 (0.62–0.88)
France 0.72 (0.42–1.24) 0.74 (0.43–1.28) 0.77 (0.45–1.33) 0.81 (0.47–1.40)
Greece 0.46 (0.33–0.63) 0.45 (0.32–0.62) 0.47 (0.34–0.65) 0.54 (0.39–0.76)
Italy 0.87 (0.65–1.15) 0.86 (0.65–1.14) 0.89 (0.67–1.18) 0.91 (0.68–1.20)
Spain 0.50 (0.29–0.87) 0.49 (0.29–0.85) 0.51 (0.30–0.89) 0.57 (0.33–0.98)
Other Southern Europe 1.03 (0.64–1.66) 1.02 (0.63–1.64) 1.03 (0.64–1.66) 1.16 (0.72–1.87)
Western Europe 1.08 (0.97–1.21) 1.11 (0.99–1.24) 1.13 (1.01–1.26) 1.14 (1.02–1.28)
The Netherlands 0.60 (0.35–1.03) 0.62 (0.36–1.06) 0.63 (0.37–1.09) 0.66 (0.38–1.14)
UK and Ireland 1.03 (0.80–1.33) 1.06 (0.82–1.37) 1.10 (0.85–1.42) 1.24 (0.96–1.61)
Germany 1.11 (0.96–1.29) 1.14 (0.99–1.32) 1.16 (1.00–1.34) 1.13 (0.98–1.31)
Austria 1.41 (1.08–1.85) 1.45 (1.10–1.90) 1.48 (1.13–1.95) 1.42 (1.08–1.87)
Other Western Europe 0.79 (0.40–1.40) 0.82 (0.47–1.45) 0.85 (0.48–1.50) 0.89 (0.51–1.57)
Eastern Europe 1.08 (0.97–1.21) 1.09 (0.98–1.22) 1.11 (1.00–1.25) 1.03 (0.92–1.15)
Bosnia 0.96 (0.72–1.29) 1.02 (0.76–1.37) 1.11 (0.83–1.49) 0.86 (0.64–1.16)
Yugoslavia 1.09 (0.95–1.25) 1.08 (0.94–1.24) 1.09 (0.95–1.26) 1.03 (0.90–1.19)
Croatia 1.46 (0.95–2.25) 1.46 (0.95–2.24) 1.45 (0.94–2.22) 1.47 (0.96–2.26)
Romania 1.42 (1.02–1.99) 1.46 (1.05–2.05) 1.48 (1.06–2.07) 1.39 (0.99–1.95)
Baltic countries 0.83 (0.63–1.08) 0.85 (0.65–1.11) 0.86 (0.66–1.13) 0.83 (0.63–1.09)
Estonia 0.78 (0.58–1.06) 0.80 (0.59–1.08) 0.81 (0.60–1.10) 0.78 (0.58–1.06)
Latvia 1.07 (0.60–1.94) 1.12 (0.62–2.02) 1.14 (0.63–2.06) 1.08 (0.60–1.95)
Central Europe 1.25 (1.09–1.43) 1.28 (1.12–1.46) 1.29 (1.13–1.47) 1.18 (1.04–1.35)
Poland 1.38 (1.14–1.66) 1.41 (1.17–1.70) 1.42 (1.18–1.72) 1.31 (1.08–1.58)
Other Central Europe 1.01 (0.72–1.42) 1.05 (0.75–1.48) 1.06 (0.75–1.49) 1.01 (0.72–1.42)
Hungary 1.22 (0.98–1.51) 1.24 (1.00–1.54) 1.24 (1.00–1.55) 1.12 (0.90–1.40)
Africa 1.33 (1.12–1.59) 1.34 (1.12–1.59) 1.40 (1.17–1.67) 1.36 (1.14–1.63)
Northern America 0.80 (0.60–1.07) 0.83 (0.62–1.11) 0.86 (0.64–1.14) 0.91 (0.68–1.22)
Latin America 0.59 (0.46–0.76) 0.59 (0.45–0.76) 0.61 (0.47–0.78) 0.66 (0.51–0.85)
Chile 0.48 (0.33–0.68) 0.47 (0.33–0.67) 0.48 (0.34–0.69) 0.52 (0.36–0.74)
South America 0.78 (0.55–1.12) 0.79 (0.55–1.13) 0.82 (0.57–1.17) 0.91 (0.64–1.31)
Asia 1.28 (1.18–1.40) 1.30 (1.19–1.42) 1.35 (1.24–1.47) 1.28 (1.17–1.39)
Turkey 0.91 (0.73–1.13) 0.89 (0.71–1.11) 0.93 (0.75–1.16) 0.89 (0.71–1.11)
Lebanon 1.03 (0.75–1.43) 1.01 (0.73–1.39) 1.04 (0.75–1.44) 0.99 (0.72–1.37)
Iran 1.10 (0.91–1.33) 1.15 (0.95–1.39) 1.17 (0.97–1.42) 1.20 (1.00–1.45)
Iraq 2.00 (1.69–2.37) 2.10 (1.77–2.48) 2.22 (1.87–2.63) 1.82 (1.54–2.16)
Other Asia countries 1.37 (1.18–1.59) 1.39 (1.20–1.61) 1.44 (1.24–1.67) 1.37 (1.18–1.59)
Russia 1.87 (1.39–2.50) 1.91 (1.43–2.56) 1.95 (1.46–2.62) 1.69 (1.26–2.27)
Regions (also including separately listed countries) marked by italicsHR (95% CI): Hazard ratios with 95%
confidence intervalStatistically significant HRs marked by italicsModel 1: adjusted for age and region of resi-
dence in Sweden; model 2: adjusted for age, region of residence in Sweden, educational level and marital status;
model 3: model 2 + neighbourhood deprivation; model 4: model 3 + co-morbidities
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could possibly be related to the healthymigrant effect, e.g. men
from Denmark and Norway and women from Northern
America. For second-generation immigrants, an adaptation to
the mainstream dietary culture could be expected, which could
explain the regression towards the reference population, i.e.
individuals with indigenous parents. Besides, comparing prev-
alence figures between studies of diagnosed gout in published
papers is difficult, as there is a large variation in the prevalence
of gout depending on different factors, including the used def-
inition of gout, the sampling methods, the studied age groups
and the sex distribution, with a higher prevalence in men [9,
21]. For instance, we emphasize that the gout prevalence of
0.5% in the present study is in accordance with the prevalence
figure worldwide found in a review, which is 0.6% [9]. The
prevalence in the present study was based on a hospital
diagnosis of gout. A similar prevalence was found in an earlier
Swedish study on reported diagnosis of gout from all care
branches, i.e. hospital in-care, specialized open care and pri-
mary care [22]. However, in that study, the prevalence was
1.4% when including all individuals ever reported with a gout
diagnosis including from primary health care being alive at the
end of the study period [22], i.e. around the same prevalence as
in the UK and Germany [15], and on the same level as in North
America and other countries in Western Europe [16].
Regarding the situation among different immigrant groups,
the higher gout prevalence in different ethnic groups, includ-
ing Filipinos and African Americans, has been attributed to
the high gout prevalence in North America [23]. The higher
risk of hyperuricemia and gout as described among Filipinos
in the USA is ascribed to the shift from a low-purine diet to a
Table 3 The risk of gout in first-
generation female immigrants Country/region of origin Model 1 Model 2 Model 3 Model 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sweden 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Nordic countries 1.05 (0.97–1.15) 1.01 (0.93–1.10) 1.03 (0.94–1.12) 0.94 (0.87–1.03)
Denmark 0.96 (0.76–1.21) 0.93 (0.74–1.17) 0.93 (0.74–1.17) 0.96 (0.76–1.21)
Finland 1.14 (1.03–1.26) 1.09 (0.98–1.20) 1.11 (1.01–1.23) 0.98 (0.89–1.09)
Norway 0.88 (0.71–1.09) 0.85 (0.69–1.06) 0.86 (0.69–1.06) 0.82 (0.66–1.02)
Southern Europe 0.53 (0.35–0.81) 0.50 (0.33–0.76) 0.52 (0.52–0.78) 0.61 (0.40–0.93)
Western Europe 1.05 (0.88–1.25) 1.09 (0.91–1.30) 1.11 (0.93–1.33) 1.09 (0.91–1.30)
The Netherlands 0.71 (0.27–1.90) 0.75 (0.28–2.00) 0.78 (0.29–2.07) 0.84 (0.32–2.24)
Germany 1.05 (0.85–1.29) 1.09 (0.88–1.34) 1.11 (0.90–1.36) 1.04 (0.84–1.28)
Austria 1.68 (1.06–2.67) 1.74 (1.10–2.77) 1.77 (1.12–2.82) 1.70 (1.07–2.70)
Eastern Europe 1.26 (1.02–1.57) 1.19 (0.96–1.48) 1.21 (0.97–1.50) 1.10 (0.89–1.36)
Bosnia 1.33 (0.77–2.30) 1.34 (0.78–2.32) 1.47 (0.85–2.54) 1.17 (0.68–2.02)
Yugoslavia 1.14 (0.86–1.50) 1.04 (0.79–1.38) 1.04 (0.79–1.38) 0.96 (0.73–1.27)
Romania 1.86 (1.06–3.28) 2.00 (1.14–3.53) 2.02 (1.14–3.55) 1.72 (0.98–3.04)
Baltic countries 0.87 (0.61–1.24) 0.94 (0.66–1.34) 0.96 (0.67–1.37) 0.89 (0.63–1.27)
Estonia 0.73 (0.48–1.11) 0.78 (0.51–1.18) 0.80 (0.52–1.21) 0.75 (0.49–1.13)
Central Europe 1.55 (1.27–1.88) 1.65 (1.36–2.01) 1.65 (1.36–2.01) 1.47 (1.21–1.79)
Poland 1.42 (1.08–1.87) 1.50 (1.14–1.98) 1.50 (1.14–1.98) 1.34 (1.01–1.76)
Other Central Europe 1.00 (0.57–1.76) 1.09 (0.62–1.92) 1.10 (0.62–1.94) 1.06 (0.60–1.86)
Hungary 2.20 (1.61–3.01) 2.34 (1.71–3.21) 2.34 (1.71–3.21) 1.98 (1.45–2.71)
Africa 2.32 (1.57–3.44) 2.15 (1.45–3.19) 2.27 (1.53–3.36) 2.23 (1.50–3.31)
Northern America 0.36 (0.18–0.72) 0.37 (0.19–0.74) 0.38 (0.19–0.76) 0.41 (0.21–0.83)
Latin America 0.82 (0.52–1.29) 0.80 (0.51–1.25) 0.82 (0.52–1.28) 0.83 (0.53–1.30)
Chile 0.90 (0.51–1.59) 0.85 (0.48–1.50) 0.87 (0.49–1.53) 0.84 (0.47–1.47)
Asia 1.40 (1.16–1.69) 1.31 (1.08–1.58) 1.35 (1.11–1.63) 1.20 (0.99–1.45)
Turkey 1.66 (1.16–2.37) 1.41 (0.99–2.03) 1.46 (1.02–2.09) 1.16 (0.81–1.66)
Iraq 2.19 (1.41–3.41) 2.12 (1.36–3.30) 2.28 (1.46–3.55) 1.76 (1.13–2.74)
Other Asia countries 1.36 (1.01–1.84) 1.29 (0.96–1.75) 1.33 (0.99–1.80) 1.30 (0.96–1.75)
Russia 0.87 (0.49–1.53) 0.93 (0.53–1.63) 0.94 (0.53–1.66) 0.84 (0.48–1.49)
Regions (also including separately listed countries) marked by italicsHR (95% CI): Hazard ratios with 95%
confidence intervalStatistically significant HRs marked by italics Model 1: adjusted for age and region of resi-
dence in Sweden; model 2: adjusted for age, region of residence in Sweden, educational level and marital status;
model 3: model 2 + neighbourhood deprivation; model 4: model 3 + co-morbidities
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high-purine Western diet, and the Filipino group seems to be
especially vulnerable when adapting a high-purine diet [23].
When trying to understand the risk pattern of gout among
the immigrant groups found in our study, the pattern of risk
factors for gout is of importance. Gout is strongly related to
lifestyle and dietary habits [24], including alcohol intake [12].
Trends in lifestyle factors, such as the increased alcohol intake
[25], and change in dietary habits, including higher intake of
sweetened soft drinks [21], contribute to increased obesity and
themetabolic syndrome in the general population. High alcohol
intake, especially of beer, is also a factor of importance for
hyperuricemia and gout, while intake of wine rather seems to
be protective [25]. According to the OECD statistics, alcohol
intake per capita was highest in Estonia and Austria in 2012,
with Hungary, Russia and Germany ranked on the seventh to
ninth places, and with a very low alcohol intake in Turkey [26].
However, pattern of intake of the different alcohol beverages
differ, with a high intake of beer in inhabitants not only in
Austria, Germany, Finland, Poland, Hungary, Russia and the
Netherlands but also in Spain; a high intake of spirits in Russia,
Hungary and Poland; and a high intake of wine and relatively
lower of other alcohol beverages in France, Greece, Italy and
Table 4 The risk of gout in
second-generation male
immigrants
Country/region of origin Model 1 Model 2 Model 3 Model 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sweden 1 (ref)
Nordic countries 1.23 (1.15–1.32) 1.20 (1.23–1.29) 1.18 (1.11–1.26) 1.17 (1.10–1.25)
Denmark 1.08 (0.92–1.27) 1.06 (0.90–1.25) 1.07 (0.91–1.25) 1.12 (0.95–1.31)
Finland 1.34 (1.23–1.45) 1.29 (1.19–1.41) 1.26 (1.16–1.37) 1.23 (1.13–1.33)
Norway 1.14 (0.99–1.31) 1.13 (0.98–1.30) 1.12 (0.97–1.29) 1.11 (0.96–1.28)
Southern Europe 0.93 (0.70–1.23) 0.92 (0.70–1.22) 0.89 (0.67–1.18) 0.97 (0.73–1.28)
Greece 0.47 (0.24–0.95) 0.46 (0.23–0.93) 0.44 (0.22–0.89) 0.50 (0.25–1.00)
Italy 1.34 (0.89–2.01) 1.32 (0.88–1.99) 1.28 (0.85–1.93) 1.39 (0.92–2.09)
Spain 1.45 (0.80–2.62) 1.43 (0.79–2.59) 1.38 (0.77–2.50) 1.45 (0.80–2.62)
Western Europe 0.96 (0.82–1.12) 0.98 (0.84–1.14) 0.96 (0.82–1.12) 1.00 (0.86–1.17)
The Netherlands 0.83 (0.41–1.66) 0.84 (0.42–1.68) 0.83 (0.41–1.65) 0.89 (0.45–1.78)
UK and Ireland 0.63 (0.36–1.12) 0.65 (0.37–1.15) 0.63 (0.36–1.12) 0.65 (0.37–1.15)
Germany 1.01 (0.84–1.21) 1.02 (0.85–1.22) 1.01 (0.84–1.21) 1.05 (0.88–1.26)
Austria 1.28 (0.85–1.93) 1.31 (0.87–1.97) 1.28 (0.85–1.93) 1.31 (0.87–1.98)
Eastern Europe 1.21 (0.97–1.52) 1.23 (0.98–1.54) 1.21 (0.97–1.51) 1.18 (0.95–1.48)
Yugoslavia 1.31 (1.02–1.70) 1.30 (1.01–1.67) 1.30 (1.00–1.67) 1.28 (0.99–1.65)
Romania 1.47 (0.73–2.93) 1.52 (0.76–3.03) 1.49 (0.75–2.99) 1.42 (0.71–2.85)
Baltic countries 1.17 (0.93–1.47) 1.20 (0.96–1.51) 1.17 (0.93–1.47) 1.20 (0.96–1.51)
Estonia 1.15 (0.90–1.48) 1.18 (0.92–1.51) 1.15 (0.90–1.48) 1.20 (0.93–1.53)
Latvia 1.29 (0.73–2.27) 1.34 (0.76–2.36) 1.31 (0.75–2.31) 1.25 (0.71–2.20)
Central Europe 1.37 (1.11–1.69) 1.40 (1.13–1.72) 1.39 (1.13–1.72) 1.36 (1.10–1.68)
Poland 1.46 (1.09–1.96) 1.52 (1.13–2.03) 1.51 (1.13–2.02) 1.45 (1.08–1.94)
Other Central Europe 1.20 (0.72–1.98) 1.22 (0.74–2.03) 1.21 (0.73–2.01) 1.24 (0.75–2.05)
Hungary 1.37 (0.94–1.98) 1.36 (0.94–1.97) 1.36 (0.94–1.97) 1.34 (0.92–1.94)
North America 0.99 (0.75–1.29) 1.01 (0.77–1.32) 1.00 (0.76–1.30) 1.02 (0.78–1.34)
Latin America 0.70 (0.41–1.18) 0.70 (0.42–1.19) 0.68 (0.40–1.15) 0.66 (0.39–1.11)
South America 1.11 (0.58–2.14) 1.15 (0.60–2.21) 1.12 (0.58–2.15) 1.11 (0.58–2.13)
Asia 1.02 (0.81–1.27) 1.04 (0.83–1.30) 1.00 (0.80–1.25) 0.95 (0.76–1.19)
Turkey 0.95 (0.63–1.44) 0.93 (0.61–1.40) 0.89 (0.59–1.35) 0.89 (0.59–1.34)
Iran 1.12 (0.65–1.93) 1.20 (0.69–2.06) 1.17 (0.68–2.01) 1.07 (0.62–1.84)
Iraq 1.34 (0.76–2.36) 1.45 (0.82–2.56) 1.34 (0.76–2.36) 1.15 (0.65–2.03)
Other Asian countries 1.10 (0.76–1.59) 1.14 (0.79–1.66) 1.10 (0.76–1.60) 1.07 (0.74–1.55)
Russia 0.85 (0.53–1.37) 0.86 (0.53–1.38) 0.85 (0.53–1.36) 0.82 (0.51–1.32)
Regions (also including separately listed countries) marked by italicsHR (95% CI): Hazard ratios with 95%
confidence intervalStatistically significant HRs marked by italics Model 1: adjusted for age and region of resi-
dence in Sweden; model 2: adjusted for age, region of residence in Sweden, educational level and marital status;
model 3: model 2 + neighbourhood deprivation; model 4: model 3 + co-morbidities
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Chile. Immigrants probably bring drinking habits from their
country of origin, which is why the alcohol intake patterns of
home countries is of importance. Thus, high intake of beer or
spirits could partly explain the higher risk of gout among im-
migrants from Finland, Austria, Poland, Hungary and Russia.
The increased prevalence of gout and hyperuricemia in
both Western and third-world societies has been linked not
only to urbanization, western lifestyle and immigration to
western countries [27] but also to higher rates of hypertension
[28]. The increased incidence and prevalence of gout world-
wide tails the obesity epidemic [11]. Even if gout has been
regarded as Bthe disease of kings^ and as such associated to
wealth and good living [29], it is nowadays more linked to
lower socio-economic status [30], which is also in line with
our findings. The risk of overweight and obesity, especially
abdominal obesity, has been shown to be higher in many im-
migrant groups of non-European origin [31]. Among non-
Western immigrants, Middle East women in general have a
higher risk of abdominal obesity [32] and diabetes [33]. When
looking at dietary patterns among immigrants, also including
second-generation immigrants, a pattern with more sugar-rich
food and beverages and more fat-rich food is seen [31]. In
Table 5 The risk of gout in
second-generation female
immigrants
Country/region of origin Model 1 Model 2 Model 3 Model 4
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Sweden 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Nordic countries 0.88 (0.76–1.03) 0.84 (0.72–0.98) 0.82 (0.70–0.96) 0.83 (0.71–0.97)
Denmark 0.74 (0.50–1.10) 0.69 (0.47–1.03) 0.69 (0.47–1.02) 0.74 (0.50–1.09)
Finland 0.94 (0.77–1.14) 0.90 (0.74–1.09) 0.87 (0.72–1.06) 0.85 (0.70–1.04)
Norway 0.89 (0.65–1.21) 0.85 (0.62–1.17) 0.85 (0.62–1.16) 0.87 (0.64–1.20)
Southern Europe 0.79 (0.42–1.47) 0.70 (0.38–1.31) 0.67 (0.36–1.25) 0.77 (0.41–1.44)
Greece 0.75 (0.24–2.33) 0.62 (0.20–1.94) 0.59 (0.19–1.84) 0.72 (0.23–2.23)
Italy 0.49 (0.12–1.98) 0.45 (0.11–1.81) 0.43 (0.11–1.74) 0.52 (0.13–2.09)
Spain 1.17 (0.29–4.70) 1.08 (0.27–4.31) 1.04 (0.26–4.16) 1.04 (0.26–4.17)
Western Europe 0.70 (0.49–1.01) 0.70 (0.49–1.01) 0.69 (0.48–0.99) 0.76 (0.53–1.09)
The Netherlands 0.87 (0.22–3.48) 0.84 (0.21–3.36) 0.82 (0.20–3.27) 0.96 (0.24–3.83)
UK and Ireland 1.06 (0.44–2.55) 1.01 (0.42–2.42) 0.97 (0.40–2.34) 1.06 (0.44–2.55)
Germany 0.64 (0.40–1.02) 0.65 (0.41–1.03) 0.64 (0.40–1.01) 0.70 (0.44–1.11)
Austria 0.68 (0.22–2.09) 0.69 (0.22–2.14) 0.68 (0.22–2.10) 0.74 (0.24–2.30)
Eastern Europe 1.11 (0.69–1.79) 1.03 (0.64–1.67) 0.99 (0.62–1.61) 1.01 (0.62–1.63)
Yugoslavia 0.94 (0.50–1.75) 0.86 (0.46–1.60) 0.84 (0.45–1.56) 0.88 (0.47–1.63)
Romania 2.30 (0.74–7.13) 2.28 (0.74–7.08) 2.21 (0.71–6.85) 2.07 (0.67–6.42)
Baltic countries 1.15 (0.73–1.80) 1.19 (0.76–1.86) 1.16 (0.74–1.82) 1.22 (0.77–1.91)
Estonia 1.06 (0.64–1.77) 1.09 (0.66–1.82) 1.07 (0.64–1.78) 1.13 (0.68–1.87)
Latvia 1.62 (0.61–4.33) 1.77 (0.66–4.71) 1.72 (0.64–4.58) 1.78 (0.67–4.75)
Central Europe 1.28 (0.82–1.99) 1.27 (0.82–1.97) 1.26 (0.81–1.96) 1.25 (0.81–1.95)
Poland 1.20 (0.62–2.30) 1.19 (0.62–2.29) 1.18 (0.61–2.26) 1.12 (0.58–2.16)
Other Central Europe 1.28 (0.48–3.42) 1.28 (0.48–3.42) 1.27 (0.48–3.38) 1.33 (0.50–3.54)
Hungary 1.42 (0.67–2.97) 1.41 (0.67–2.96) 1.40 (0.67–2.95) 1.45 (0.69–3.05)
North America 0.75 (0.41–1.35) 0.75 (0.42–1.36) 0.74 (0.41–1.34) 0.80 (0.44–1.44)
Latin America 1.32 (0.59–2.94) 1.17 (0.52–2.61) 1.12 (0.50–2.50) 1.05 (0.47–2.35)
South America 1.62 (0.52–5.04) 1.47 (0.47–4.57) 1.42 (0.46–4.40) 1.42 (0.46–4.41)
Asia 1.42 (0.95–2.11) 1.25 (0.83–1.86) 1.18 (0.79–1.77) 1.10 (0.74–1.65)
Turkey 2.04 (1.13–3.70) 1.74 (0.96–3.16) 1.66 (0.91–3.01) 1.61 (0.89–2.92)
Iran 0.40 (0.06–2.79) 0.37 (0.05–2.62) 0.36 (0.05–2.52) 0.32 (0.05–2.24)
Iraq 1.38 (0.44–4.30) 1.18 (0.38–3.67) 1.09 (0.35–3.41) 0.94 (0.30–2.94)
Other Asian countries 1.70 (0.91–3.17) 1.54 (0.83–2.88) 1.48 (0.79–2.76) 1.42 (0.76–2.66)
Russia 0.92 (0.38–2.21) 0.93 (0.39–2.23) 0.91 (0.38–2.19) 0.87 (0.36–2.09)
Regions (also including separately listed countries) marked by italicsHR (95% CI): Hazard ratios with 95%
confidence intervalStatistically significant HRs marked by italics Model 1: adjusted for age and region of resi-
dence in Sweden; model 2: adjusted for age, region of residence in Sweden, educational level and marital status;
model 3: model 2 + neighbourhood deprivation; model 4: model 3 + co-morbidities
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general, it seems that dietary habits among non-Western im-
migrant groups in Europe are likely to become less healthy
[34]. Dietary habits among second-generation immigrants al-
so tend to approach those found in age- and sex-matched
individuals in the indigenous population [35]. In contrast,
the prevalence of hypertension is lower among immigrants
of non-European origin in Sweden [36], i.e. one important
factor that could explain the lower risk of gout among some
groups. As hyperuricemia and gout also is associated with
CVD and CHD, patterns of these among different countries
are of importance. According to recent statistics from the
OECD, the CHD mortality is higher in Finland, the Baltic
countries, Eastern Europe, Hungary and Turkey than in
Sweden; while a lower CHD mortality is reported from the
Nordic countries with the exception of Finland, Southern
Europe and Chile [37].
When looking at the specific immigrant groups and the risk
of gout, among Turkish born women an increased risk of
abdominal obesity and the metabolic syndrome [38] and also
of diabetes [39], has been reported. Besides, among Iraqi im-
migrants, an increased risk of pre-diabetes and diabetes has
been reported [40]. A higher risk of abdominal obesity is also
found among immigrants, especially in women, from Eastern
Europe, in that study also, including immigrants from Poland,
Hungary and Russia [32], and a higher body mass index
(BMI) among Polish men [41]. The lower estimates in some
of these groups when adjusting for co-morbidities could sup-
port that obesity may partly explain the excess risk.
Otherwise, the estimates were only marginally changed when
adjusting for co-morbidities. As regards the lower risk of gout
among South Europeans, adherence to Mediterranean diet is
associated with a lower risk of hyperuricemia [42].
There are some limitations in this study. As we divided into
many different immigrant groups, there is a risk of mass signif-
icance when using the p level < 0.05. Thus, the results should be
interpreted with caution owing to the multiple testing. The statis-
tical power to detect significant results also differed between the
immigrant groups owing to varying sample size, and the power
was lower among women, especially second-generation women.
We used hospital diagnoses to identify individuals with gout, and
it is possible that other groups would have been identified if we
had access to diagnoses in other care forms, especially primary
care. As diagnoseswere taken from theNational Patient Register,
they are clinically based and we cannot check for the criteria for
gout diagnosis being used. Furthermore, we had no access to
prescription of allopurinol, but when this was actual, the diagno-
sis was probably set. We adjusted for co-morbidities which can
be discussed as the association between gout and co-morbidities
may go in both directions, i.e. may be a risk factor for gout or a
consequence of gout. However, results when adjusted for co-
morbidities were similar in most cases. Despite the limitations,
this is one of rare studies in Europe providing insight in differ-
ences in gout among different immigrant groups. A strength of
the study is that we used neighbourhood SES that is a proxy for
lifestyle factors [43], and it has been shown to be associatedwith,
for example smoking [44, 45].
In conclusion, the results of this study indicate sig-
nificant differences in risks of gout between immigrants
and Swedish-born groups, which are more prominent
between first-generation immigrant men and women
and their Swedish counterparts. As gout is a risk factor
for cardio-vascular diseases, including an increased mor-
tality risk [10], identifying patients with hyperuricemia
and gout is one way to be able to prevent these dis-
eases. The differences observed may be related to dif-
ferences between immigrants and Swedish born in the
interplay between genetics and environment, risk factors
for gout or provision of medical care. As gout causes
suffering for the individuals and increased cost for so-
ciety, measures in preventing gout, especially by health-
ier lifestyle habits, could be an effective way to entan-
gle the problem. As the risk of gout is increased among
some immigrant groups, it is important to draw attention
to this, to reassure equity in health in the population. A
healthier lifestyle in the whole population is desirable,
but to reach this goal, interventions might need to be tailored
for specific groups.
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